Entering text into the input field will update the search result below

Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2020 Results - Earnings Call Transcript

May 08, 2020 3:31 AM ETNektar Therapeutics (NKTR) Stock
SA Transcripts profile picture
SA Transcripts

Nektar Therapeutics (NASDAQ:NKTR) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET

Company Participants

Jennifer Ruddock - SVP, Strategy & Corporate Affairs

Howard Robin - President & CEO

Wei Lin - SVP & Head of Development

Jonathan Zalevsky - Chief R&D Officer

Gil Labrucherie - COO & CFO

Conference Call Participants

Peter Lawson - Barclays

Tyler Van Buren - Piper Sandler

Chris Shibutani - Cowen

Difei Yang - Mizuho

Bert Hazlett - BTIG

George Farmer - BMO Capital Markets

Arlinda Lee - Canaccord

Aydin Huseynov - Benchmark

Jay Olson - Oppenheimer

Daina Graybosch - SVB Leerink


Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics First Quarter 2020 Financial Results Conference Call. At this time, all participants lines are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Corporate Affairs. Ma'am, you may begin.

Jennifer Ruddock

Thank you, Crystal. Good afternoon, everyone, and thank you for joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Head of R&D; and Dr. Wei Lin, our Head of Development. On today's call, we expect to make forward-looking statements regarding our business, including clinical trial results, timing and plans for future clinical trials, timing and plans for future clinical data presentations, the therapeutic potential of our drug candidates, outcomes and plans for health authority regulatory actions and decisions, estimates and predictions of the COVID-19 pandemic's impact on our business and clinical trials, financial guidance and certain other statements regarding the future of our business.

Because these statements

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About NKTR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on NKTR

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.